| HOME >> BIOLOGY >> TECHNOLOGY |
Testing Will Help Advance Technology to Find a Faster, More Accurate and Repeatable Method for Drug-Particle Sizing
PITTSBURGH, April 1 /PRNewswire/ -- ChemImage, (www.chemimage.com) today announces a strategic research partnership with Next Breath, LLC (www.nextbreath.net), a leading Contract Research Organization (CRO) to further validate ChemImage's Raman Chemical Imaging for bioequivalence applications for nasal spray suspensions.
Baltimore, MD-based Next Breath focuses on conducting in vitro bioequivalence testing for nasal sprays and chemistry, manufacturing and controls (CMC) testing for inhalation and nasal spray products, and is particularly interested in advancing the technology to find a faster and reproducible method for drug-particle sizing relative to bioequivalence studies for nasal spray suspensions.
"We are proud to partner with Next Breath because our goal at ChemImage is to validate our bioequivalence testing methodology," said Ryan Priore, Senior Scientist, ChemImage. "Pharmaceutical companies, particularly generic drug manufacturers focused on nasal spray suspensions, are looking to improve their time-to-market through the use of better imaging technology. The potential payoff is a faster, more accurate and safe way to bring the drug to market."
ChemImage, one of the world's leading chemical and biological imaging technology solutions companies, will be partnering with Next Breath to compare optical microscopy to Raman Chemical Imaging, specifically ChemImage's FALCON II(TM) Wide-Field Raman Chemical Imaging System.
The FALCON II enables drug manufacturers to perform chemical imaging of particles in droplets to distinguish the identity, particle size distribution of drug and other substances, aggregation, and the correlation about the location of t
'/>"/>
| SOURCE ChemImage Copyright©2009 PR Newswire. All rights reserved |